Glaucoma Trial, Recruiting NCT06128720 Sponsor: Stanford University Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT06128720
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who are able to follow the study schedule and complete all required visits and tasks
  • People who have clinical signs of optic neuropathy (damage to the nerve that carries vision signals from the eye to the brain)
  • People who are able to read and sign a consent form — or, if vision is too impaired to read it, the document will be read aloud to them in full

Who may not be able to join:

  • People who are unable to follow the study procedures or attend the required follow-up visits
  • People who have cloudiness or lack of clarity in the cornea (the clear front surface of the eye)
  • People who are currently in another clinical drug trial, or who have taken part in one in the last 3 months, where the drug was given by eye drops (in the study eye) or taken by the whole body
  • People who are pregnant or breastfeeding
  • People who have a physical or mental health condition that, in the opinion of the study doctor, could increase the risks of taking part or affect the study results
  • Children and people who are in a coma
  • People who are currently misusing drugs or alcohol
  • People who have received hyperbaric oxygen treatment (a therapy involving breathing pure oxygen in a pressurised chamber) within the last 6 months
  • People who have claustrophobia or who are unable to equalise ear pressure properly (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jeffrey L Goldberg, MD PhD, Stanford University

Phone: 6504975942

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2022
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Visual Field- Mean Deviation; Change in Visual Field- Visual Field Index

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov